Compare AVX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | BCTX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 28.8M |
| IPO Year | 2020 | 2025 |
| Metric | AVX | BCTX |
|---|---|---|
| Price | $3.23 | $3.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 167.1K | 63.1K |
| Earning Date | 11-12-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,340,811.00 | N/A |
| Revenue This Year | $18,042.77 | N/A |
| Revenue Next Year | $12.21 | $250.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3348.10 | N/A |
| 52 Week Low | $0.35 | $2.60 |
| 52 Week High | $7.38 | $13.09 |
| Indicator | AVX | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 41.47 |
| Support Level | $3.02 | $2.97 |
| Resistance Level | $3.96 | $3.74 |
| Average True Range (ATR) | 0.53 | 0.28 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 6.88 | 16.36 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.